The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
We know the easy way is to change the inferred title so to push their attempts off the page. As soon as we see negativity without back up just filter and change the story. They will try and change it back as the battle will always be on.
Not afraid of balanced opinions backed with evidence but blatant negativity from 1 post wonders......nah!
Enjoy your afternoon
Hi RMM
Another well researched and sensibly balanced view of our current pipeline’s potential value. Personally, I appreciate your opinions and it aligns with other valuations and opinions of investors here and market deals that we see regularly for other similar compounds.
What makes us slightly different from others is we have 3 current targets for our TYK2s, Covid, autoimmune and cancer, with autoimmune and cancer having over 80+ conditions/indications/diseases that could be treated (as described in their individual patents). As you correctly state, we only need to be proved up a few of these and we will be worth £Billions. The value being in the IP and duration of patents.
Enjoy your walk and stay safe.
All those looking for a lower entry - read very carefully, this company will become world renowned very soon (IMHO)
GLA
Hi Potnak
I’m not expecting any miracles from tweeting media outlets and influential individuals, but rather just raising awareness. I’m sure the UKRI would have been sharing the data with those who need to know, but on the flip side there won’t be many except only us invested and some traders who will know the implications of the news.
For me personally, the news about us being superior to dexamethasone is absolutely incredible when you consider the process the medical profession undertook to find which drugs had an impact on covid. From memory they scanned tens of thousands of drugs, this puts us in a different league to existing drugs.
Looking forward to the coming weeks and wish all of us the best.
Hi All - I’m continuing my quest of emailing the UK media and sent my email noted below (earlier post) to Thomas Moore at Sky News.
As I don’t use Twitter can one of the team ping him
@SkyNewsThomas
We need to get this news out and at least let them start their own enquiries. The news of being superior to dexamethasone needs to get out in msm.
GLA
Hi Team
I have sent an email to the Daily Mail UK Health editor and his Asst Health editor to raise the profile of what SAR have achieved. Below is the content.
Can some of you with Twitter also flick it on to them. Would be great to see some media exposure on what is excellent news. Send to @StematTheWS94 and @Connor_Boyd_
Dear Connor
please see the email below that was originally for Sam. Maybe you would be interested in following up the groundbreaking and world changing story?
Regards
Begin forwarded message:
From:
Date: 2 July 2021 at 1:42:36 PM NZST
To: stephen.matthews@mailonline.co.uk
Subject: Fwd: Covid therapy pill by Autumn - UK based proof of concept COMPLETED by Sareum funded by UKRI
? Dear Stephen - please see the email below that was for Sam. Maybe you would be interested in following up the groundbreaking and world changing story?
Regards
Begin forwarded message:
From:
Date: 2 July 2021 at 1:40:13 PM NZST
To: sam.blanchard@mailonline.co.uk
Subject: Re: Covid therapy pill by Autumn - UK based proof of concept COMPLETED by Sareum funded by UKRI
? Dear Sam
Hope you staying safe and doing well.
Further to my detailed email below, I thought you maybe interested to know that the UKRI grant funded experiments have now finished and Sareum announced the results yesterday (01 July - 7:00am)
More details can be found on the Sareum website but in a nutshell:
The aim of this research project was to investigate the effects of SDC-1801, the Company's proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a 'cytokine storm') via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801.
The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company's Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.
Subsequent completed in-vivo studies support the initial cellular results and indicate:
· Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and that
· Viral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response
I feel this now aligns to the UK Government desire for covid therapeutics and I would be pleased to see the Daily Mail taking a lead on this story that could see an end to the global pandemic and return of both economic stability and normality.
Regards
Hi All
What people need to understand about Sareum’s drugs is that these JAK Inhibitors are considered the next generation of medicine advancement, similar to the penicillins a few decades ago.
There are 1st generation JAK inhibitors on the market but these are considered ‘dirty’ or unselective inhibitors and as such have serious side effects and carrying black box warnings for prescribing doctors. However they are still prescribed as there are little alternatives for the patients in need. Our JAK inhibitors are considered 2nd generation and ‘clean’ or more selective in comparison to the 1st generation. During preclinical trials, we could not reach a maximum tolerable dose for our drugs and at the time our CEO commented ‘it’s a good problem to have’.
We actually have 2 of these JAK inhibitors, one is known as SDC-1801 which can be used to potentially treat over 30 autoimmune conditions/indications/diseases as mentioned in its patent. The other is known as SDC-1802 and can be used again as its patent describes to treat over 55 types of cancer, especially blood cancers.
The Covid experiments were always a side play for Sareum. Our drug SDC-1801 was selected by the UK Government (UKRI) for testing against Covid and these were the Proof of Concept results that were issued today. It works……and moreover is considered superior to Dexamethasone and Baricitinib.
Dexamethasone is approved to be used to reduce inflammation and suppress (lower) the body's immune response. It was tested in hospitalised patients with COVID-19 in the UK’s national clinical trial RECOVERY and was found to have benefits for critically ill patients. According to preliminary findings shared with WHO, for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth. In fact we had previously trialled our drugs in combination with Dexamethasone (for autoimmune indications) and the trials proved successful. We have today been informed and had confirmation that our SDC-1801 is ‘superior’ to dexamethasone.
On November 19, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the use of Baricitinib in combination with Remdesivir in hospitalised adults and children with COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation. The known and potential benefits of baricitinib + remdesivir to treat COVID-19 in such patients outweigh the known and potential risks. Baricitinib is a JAK inhibitor. Baricitinib (Olumiant) is approved by the FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies1.
Currently, no adequate, approved, and available alternative to the emergency use of baricitinib + remdesivir is available.
GLA
Hi All
You all know I’ve stated a few times (IMHO) that the cabinet spin doctors will be orchestrating this excellent news.
Strange we had been fed by SAR ‘all on track for the end of June’ then bang on 01 July news drops with the inference of AGILE trials anytime from now, after chatting with the experts - mmmmm
They had to get this out today and probably agonised over wording it, couldn’t give the game away and steal the government thunder. IMHO tomorrow could be a good news day......
ATB
Reports today that the government and NHS are making plans to have millions jabbed for a 3rd time to keep covid at bay........this is a massive sign that the vaccines are not the end of Covid or a return to freedom and normality.
Again, the very reason Boris formed the Antiviral Taskforce. He is constantly advised of what the real prognosis is and it doesn’t look good in terms of relaxing restrictions and economic recovery. He needs covid therapeutics and we just proved our SDC-1801 is superior to the current best option.
What more do you need to know?
Yes Zylo
I have learnt over the years that SAR RNS’s have to be read very carefully, usually it’s not what they say but rather what they don’t say that gives the news.......for sure the UKRI will be all over the results, sharing with government scientists and the cabinet......with winter approaching and cases increasing it will be a matter of days until we get confirmation. This is exactly why Boris created the antivirals taskforce
GLA
Hi All - the reference to the trials in early 2022 are for our own funded trials in auto immune indications.
The covid trials could start at anytime following consultation with the experts (eg antivirals taskforce/AGILE/UKRI).......expect news very soon on this front as Boris has made his position clear and that was before the Delta variant and delayed freedom day. Pressure is increasing on the government and the risk decreases for us.
GLA
It is the cytokine storm that causes the pneumonia (you drown in your own mucus which is the overreacting immune system) our drug in the PRIMARY experiments proved to be superior than dexamathasone at dampening the immune reaction to covid
GLA